Our July Newsletter

Summer is here, but the great news at SOPHiA GENETICS are not slowing down! We're thrilled to share our latest advancements and collaborations that continue to push the boundaries of data-driven medicine. Don’t miss Jurgi Camblong ’s, our CEO and Co-founder, insightful post about our partnership in Basque Country which bridges academia and industry, plus our recent customer testimonial from Hospices Civils de Lyon - HCL .

The Health Policy Partnership

We are thrilled to collaborate with industry leaders such as 阿斯利康 , GE医疗 , Ibex Medical Analytics , on The Health Policy Partnership . The aim is to support a report outlining the necessary policy actions for the future of cancer diagnosis.

The report, "Powering the Future of Cancer Care with Advanced Diagnostics," details five priority areas for policymakers to support the widespread adoption of innovative techniques to support advanced diagnostics.

Read the report .

Supporting Basque Talents through Strong Partnerships

SOPHiA GENETICS , Mondragon Goi Eskola Politeknikoa , and ESTIA - école Supérieure des Technologies Industrielles Avancées are now official partners, supporting talents in the Basque Country.

This collaboration creates opportunities for inspiring talks, hands-on internships, and collaborative projects, empowering young talents in the Basque Country and beyond.

See pictures from the event in Bidart.

GIInger? for Enhanced HRD Analysis

Is your HRD analysis missing something? Meet GIInger? — a cutting-edge, deep learning algorithm that measures genomic instability in ovarian cancer samples using low-pass whole genome sequencing data.

GIInger? seamlessly integrates with different capture-based workflows, providing a universal approach to genomic instability measurement that complements your BRCA analysis for a complete HRD assessment.

?? Ready to add the missing spice to your workflow?

Oncopole Adopts MSK-ACCESS? powered with SOPHiA DDM?

Oncopole in Toulouse is the first French hospital to adopt MSK-ACCESS? powered with SOPHiA DDM?! This comprehensive cancer center, with over 2,000 professionals, treats more than 10,000 patients annually.

Professor Gilles Favre , Med. Biol., PhD., Scientific Director of IUCT-Oncopole , highlights how this liquid biopsy will enhance their research and personalized patient care. MSK-ACCESS? powered with SOPHiA DDM? combines the deep sequencing of 146 key cancer-associated genes for precise cancer analysis.

Find out more .

Launch of Residual Acute Myeloid (RAM) Application

We have launched our new Residual Acute Myeloid (RAM) Application, expanding our oncology portfolio to support measurable residual disease (MRD) capabilities. This solution will help monitor cancer and stay ahead of relapse, available worldwide starting this July.

Our RAM solution provides longitudinal variant monitoring, allowing visualization of the mutational landscape over time, and includes customizable reporting features for comprehensive MRD reports.

Learn more .

Poster Presentation at the ClinPGx Event

At the recent ClinPGx event in Philadelphia, Dr. Jean-Christophe Boyer from RNPGx presented a poster on the identification of a new CYP2D6/CYP2D7 hybrid.

This presentation is part of our ongoing commitment to advancing pharmacogenomics and precision medicine.

Starting July 3rd, the new SOPHiA DDM? Pharmacogenomics Application will be available, featuring a 41-gene panel, an accurate CYP2D6/CYP2D7 conversion module, and more.

Follow our LinkedIn page for more exciting updates!

Successful Liquid Biopsy Community Forum

Our first Liquid Biopsy Community Forum was a resounding success, bringing together 80+ experts worldwide to share insights and build connections. Presentations from early access users of MSK-ACCESS? powered with SOPHiA DDM? highlighted its impact.

Learn more about MSK-ACCESS? powered with SOPHiA DDM?.

If you're as passionate about transforming healthcare as we are, don't miss out on our future updates. ?? Subscribe to our monthly newsletter and stay at the forefront of data-driven medicine.